We project LOQTORZI in just the NPC indication alone will grow to about $150 million to $200 million annually over the next three years.
— Denny Lanfear
03Detailed Report
CHRS
Company CHRS
Period
Q1 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedMay 14, 2026
Swipe to view all report sections
Executive Summary
Coherus delivered a transitional Q1 2025 as it completes the strategic divestiture of its UDENYCA biosimilar franchise and pivots toward its innovative oncology portfolio anchored by LOQTORZI (toripalimab). Reported revenue of $7.60 million for Q1 2025, accompanied by a gross margin of 65.1%, but a sizable operating loss driven by ongoing R&D investments and the costs associated with the strategic realignment. Management highlighted a 15% growth in end-user demand for LOQTORZI in NPC and reaffirmed a long-term NPC market opportunity of roughly $150–$200 million annually, underscoring the potential for non-dilutive funding from LOQTORZI to support pipeline advancement. The company also provided an optimistic read on CHS-114 (CCR8 antibody) and Casdozokitug (anti-IL-27) programs, including AACR data illustrating Treg depletion and CD8+ T cell infiltration, which support combination strategies with toripalimab and broader immuno-oncology partnerships.
Key strategic takeaways: (1) a completed divestiture enabling a leaner cost structure with anticipated SG&A savings of about $25 million annually by year-end 2025; (2) ongoing emphasis on expanding LOQTORZI indications and payer/physician education to improve adoption despite a short-term post-restructure headwind; (3) near-term catalysts include biomarker- and efficacy-readouts for CHS-114 and Casdozokitug in HCC/NSCLC, with first PK/PD dose decisions for CHS-114 due in early 2026 under the Project Optimus framework; (4) balancing near-term cash burn with a path to profitability through LOQTORZI-driven gross margins in NPC and potential label expansions.
Overall, CHRS remains in an early-stage profitability trajectory, with meaningful upside contingent on successful execution of its innovative oncology pipeline, continued monetization of LOQTORZI, and efficient containment of SG&A and R&D spend as portfolio prioritization progresses. This report provides a detailed view of the financial and strategic levers shaping CHRS’s investment thesis for 2025–2026.
Key Performance Indicators
Revenue
Decreasing
7.60M
QoQ: -85.97% | YoY: -90.14%
Gross Profit
Decreasing
4.95M
65.09% margin
QoQ: -74.31% | YoY: -87.93%
Operating Income
Decreasing
-45.44M
QoQ: -7.55% | YoY: -27.18%
Net Income
Decreasing
-56.57M
QoQ: -11.58% | YoY: -154.99%
EPS
Decreasing
-0.49
QoQ: -11.36% | YoY: -153.85%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue and gross profitability
- Q1 2025 revenue: $7.60 million; YoY change: -90.14%; QoQ change: -85.97% (per earnings metrics). Gross profit: $4.946 million; gross margin: 65.1% (0.651).
- Revenue drivers: LOQTORZI demand grew 15% in end-user terms during Q1 2025, offset by an inventory drawdown; management noted that the NPC market is expanding with new accounts and longer duration on therapy.
Cost structure and operating loss
- R&D expenses (continuing ops): $24.356 million; R&D intensity remains high as CHS-114 and Casdozokitug advance in early-to-mid stage trials.
- SG&A (continuing ops): $26.0 million; lower year-over-year due to headcount reductions and nonrecurring charges in the prior year.
- Operating expenses (continuing ops): $50.381 million; EBITDA: -$44.202 million; Operating income: -$45.435 million; operating margin: -5.98% (–5.98%).
Net income and earnings per share
- Net income (continuing operations): -$56.569 million; net income margin: -7.44%.
- EPS (diluted): -$0.49. Weighted average shares outstanding: 115.858 million.
Discontinued operations and divestiture effects
- Net loss from discontinued operations for Q1 2025: -$9.2 million (vs Q1 2024 net income of $170.9 million, driven by a $153.6 million gain on sale of CIMERLI in 2024).
- Net revenues from discontinued ops: $32.1 million in Q1 2025 vs $24.8 million in Q1 2024 (driven by UDENYCA divestiture and subsequent wholesaler allocations).
Liquidity and balance sheet
- Cash and cash equivalents: $82.411 million; total assets: $371.066 million; total liabilities: $554.536 million; total stockholders’ equity: -$183.470 million.
- Total debt: $269.927 million; net debt: $187.516 million; liquidity remains constrained by negative equity but supported by the divestiture proceeds and ongoing cost savings.
Cash flow profile
- Net cash provided by operating activities: -$25.826 million; free cash flow: -$25.826 million.
- Cash at end of period: $82.674 million; cash at beginning: $126.250 million; operating cash flow per share: -$0.223; free cash flow per share: -$0.223.
Capital allocation and interim guidance
- Pro forma impact of UDENYCA divestiture completed in Q2 2025; upfront cash received: $483 million; additional actions included stock repurchases and debt refinancings (convertible notes repurchase of $170 million; remaining $60 million targeted for repurchase by mid-May; $48 million paid to buy remaining UDENYCA royalty).
- Expected annualized SG&A savings from headcount reductions: ~$25 million; full annualized benefit by year-end 2025; 90–100 million SG&A for full year 2025 on a continuing-operations basis (excluding reimbursed transition services costs).
- Corporate focus remains on LOQTORZI profitability and pipeline value creation; R&D is data-driven and will adjust per readouts and prioritization.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
7.60M
-90.14%
-85.97%
Gross Profit
4.95M
-87.93%
-74.31%
Operating Income
-45.44M
-27.18%
-7.55%
Net Income
-56.57M
-154.99%
-11.58%
EPS
-0.49
-153.85%
-11.36%
Key Financial Ratios
Gross Profit Margin
Excellent
65.10%
Gross profit margin is exceptional, indicating strong pricing power and operational efficiency
Operating Profit Margin
Weak
-5.98%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-7.44%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.15%
Return on assets suggests inefficient capital allocation
Return on Equity
Strong
30.80%
Return on equity demonstrates excellent capital efficiency and value creation
Current Ratio
Adequate
1.22
Current ratio meets minimum requirements but limited cushion
Debt to Equity
Conservative
-1.47
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-0.41x
Negative earnings make P/E ratio not meaningful
Price to Book
Undervalued
-0.51x
Trading below book value, potential value opportunity or distressed
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.
Coherus Oncology Inc (CHRS) QQ4 2024 Results — Transitioning to a Commercial-Stage Oncology Company with LOQTORZI Momentum and UDENYCA Divestiture P...